• Contents
• Letter of transmittal
• User guide
• Part 1: Overview
• Part 2: Highlights of 2010–2011
• Part 3: Performance
• Part 4: Horizon scanning
• Part 5: Corporate governance
• Part 6: Financial management and accountability
• Appendices
  • A1 The National Blood Agreement: objectives of governments
  • A2 Blood sector stakeholders and governance
  • A3 National Blood Authority agency resource statement
  • A4 Biographies of NBA Board members
  • A5 Fresh blood components supplied under contract by the Blood Service in 2010–11
  • A6 Plasma and recombinant products supplied under contract in 2010–11
  • A7 Units of red cells, platelets and IVIg issued per 1000 head of population 203 by state and territory 2007–08 to 2010–11
  • A8 Biographies of NBA senior managers
  • A9 Responsibilities and composition of NBA governance committees
  • A10 Mandatory reporting:
  • A11 Errata
  • A12 Glossary of terms and acronyms
  • A13 List of requirements

appendicies

APPENDIX 2. BLOOD SECTOR STAKEHOLDERS AND GOVERNANCE

Stakeholders

Australian, state and territory governments

As signatories to the National Blood Agreement, the Australian, state and territory governments are responsible for:

• establishing the policy framework and specific policies relating to the national blood supply
• overseeing the NBA’s management of the blood supply arrangements
• fostering the development and implementation of best-practice systems to promote efficient use and minimal wastage of blood and blood products
• providing information on demand for blood and blood products
• managing local issues.

Therapeutic Goods Administration (TGA)

The TGA is the regulator for blood and blood products in Australia. It is responsible for:

• regulating the efficacy and safety of blood and blood products under the Therapeutic Goods Act 1989
• auditing supplies against good manufacturing practice
• issuing product recalls
• issuing modifications to safety standards
• issuing directives such as those relating to donor deferral.

Suppliers of blood and blood products in Australia

The NBA contracts with a number of suppliers for the provision of blood and blood products including:

• the Blood Service which collects fresh blood from voluntary donors
• CSL Limited, which fractionates plasma from blood collected by the Blood Service and supplies a range of plasma products purchased through the NBA contract with CSL Limited.

During the year, the NBA has held contracts with suppliers for the provision of blood and blood products under standing offer arrangements with:

• Octapharma Australia and Lateral Diagnostics for the provision of overseas-sourced intravenous immunoglobulin (IVIg)
• Baxter Healthcare, Pfizer Australia and Novo Nordisk Pharmaceuticals Pty Ltd, for the provision of a range of imported plasma-derived and recombinant blood products
• CSL Limited, Lateral Diagnostics, Johnson & Johnson Medical (trading as Ortho-Clinical Diagnostics) and Abacus ALS Pty Ltd, for the supply of diagnostic reagents.

Governance

The key governing bodies in the Australian blood sector and their roles and relationships with each other are set out in the National Blood Agreement and the National Blood Authority Act 2003.

Australian Health Ministers’ Conference

The Australian Health Ministers’ Conference (AHMC) is responsible for overseeing and managing the blood sector. It sets the governance, policy and financial frameworks under which the NBA operates. In 2010–11 health ministers:

• approved the 2010–11 to 2012–13 Statement of Expectations for the Australian Red Cross Blood Service
• endorsed the proposed combined government response and plan to implement the recommendations of the Administrative Review of the National Blood Arrangements 2009
• approved the Statement on national stewardship expectations for the supply of blood and blood products
• agreed to the recommended nominations for membership to the NBA Board
• approved the NSP&B 2011–12
• approved the policy principles of the output based funding model.

The Hon Catherine King MP, Parliamentary Secretary to the Minister for Health and Ageing, the Hon Nicola Roxon MP, had executive responsibility for the NBA within the Australian Government health portfolio from 14 September 2010. Prior to this date the Hon Mark Butler MP was Parliamentary Secretary for Health and Ageing.

Australian Health Ministers’ Advisory Council

The Australian Health Ministers’ Advisory Council (AHMAC) provides support to the AHMC. It advises the health ministers on strategic matters relating to the coordination of health services across the nation and, as necessary, with New Zealand. The Council considers blood sector matters referred to it by the JBC through the CTEPC, and reports as necessary to the AHMC. The Council has no statutory power and decisions are reached by consensus.

Clinical, Technical and Ethical Principal Committee

The Clinical, Technical and Ethical Principal Committee (CTEPC) was established in 2006 to provide advice to the Australian Health Ministers’ Advisory Council on a range of issues, such as:

• the clinical, technical and medico-ethical developments that are likely to affect more than one jurisdiction
• options for ongoing coordination of the clinical and technical services that are managed on a national basis
• the appropriateness, effectiveness and safety of clinical and technical developments and any policy implications arising from such issues
• the impact of clinical and technical developments on the delivery and management of health care and other services
• the impact of these developments outside the health care sector.

Jurisdictional Blood Committee

Australian, state and territory governments are represented on the JBC, which was established by the National Blood Agreement in 2003. The JBC is the conduit between governments and the NBA. It represents the Australian, state and territory governments’ positions on blood policy, demand, supply planning and product distribution, funding and evidence-based approaches to emerging products, services and technologies. It oversees the NBA’s role in blood supply contracting. It is also the primary body responsible for providing advice and support on these matters to the AHMC through the CTEPC, of which it has been a subcommittee since September 2006, and the AHMAC.

Following a recommendation of the Administrative Review of the National Blood Arrangements 2009, communication links between CTEPC and the JBC were strengthened by appointing a representative of CTEPC to attend JBC meetings. During 2010–11 Dr Stephen Christley attended JBC meetings. In addition, the chair of the JBC attends relevant CTEPC meetings.

Members of the JBC serve on various NBA committees and working groups and are a highly respected and valuable source of advice and expertise. During the year, several long-standing members stepped down including Mr Bill Heiler (NSW) and Mr Tony Sansom (Tas). Ms Bedford of WA was due to retire early in July 2011.

The members of the committee at 30 June 2011 were:

• Ms Mary McDonald (Chair) Commonwealth
• Ms Donna Burton Commonwealth
• Ms Carolyn Duck Australian Capital Territory
• Ms Kim Stewart New South Wales
• Ms Kelly Burns Northern Territory
• Mr Geoff Simon Queensland
• Ms Susan Ireland South Australia
• Dr Priya Dubey Tasmania
• Ms Karen Botting Victoria
• Ms Joan Bedford Western Australia